Press Release Archive
-
Johnson & Johnson Reports 2018 Third-Quarter Results:
-
U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
-
JANSSEN TO HIGHLIGHT DATA FROM BROAD RHEUMATOLOGY PORTFOLIO AT THE 2018 ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY
-
NEW PHASE 3 DATA SHOW SINGLE DOSE OF STELARA® (USTEKINUMAB) INDUCES CLINICAL REMISSION AND RESPONSE IN ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
-
Janssen Submits European Marketing Authorisation Application for Esketamine Nasal Spray for Treatment-Resistant Depression
-
Janssen Announces Exclusive, Worldwide License Agreement with Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
-
Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1
-
Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity
-
Where will the next big idea in healthcare come from? Johnson & Johnson is counting on nurses.
-
Janssen Elects Not to Continue Agreement with Geron for Imetelstat